原代地鼠肾细胞疫苗中残余宿主细胞蛋白检测方法的建立及初步验证

目的 建立定量检测原代地鼠肾细胞(primary hamster kidney cell,PHKC)疫苗中残余宿主细胞蛋白含量的方法 .方法 制备PHKC蛋白免疫家兔,对获得的抗血清进行纯化并标记辣根过氧化物酶,通过优化各反应条件建立ELISA方法 ,同时进行方法学验证.结果 ELISA检测方法的最佳包被抗体质量浓度为6 mg/L,酶标抗体工作浓度为1:2000,最佳检测区间为12.500～200.000μg/L,定量限度为23.250μg/L,准确度和精密度较佳.结论 建立了一种简单、准确、可靠检测PHKC病毒性疫苗中宿主细胞蛋白残留量的ELISA双抗体夹心法.     

应用ELISA法检测门冬酰胺酶中残余大肠杆菌菌体蛋白含量的研究

采用Cygnus公司"大肠杆菌菌体残留蛋白检测试剂盒"检测门冬酰胺酶中残余宿主菌菌体蛋白含量,建立门冬酰胺酶中宿主菌菌体蛋白残留检测方法并进行了相关方法验证。验证结果表明:宿主菌菌体蛋白浓度在0～100 ng/mL范围内呈良好的线性关系,线性相关系数大于0.99,不同实验人员测得的精密度RSD均小于5%,平均回收率为94.34%。通过对8批门冬酰胺酶样品的检测,测得门冬酰胺酶中的残余宿主菌体蛋白含量均小于550×10-6。该方法具有快速,操作安全简便等优点,灵敏度高,重现性好,可用于门冬酰胺酶的宿主菌体蛋白的残留检测。     

检测大肠杆菌菌体蛋白的夹心ELISA试剂盒的建立及应用研究

目的  建立特异、敏感的检测大肠杆菌菌体蛋白的夹心ELISA试剂盒。方法  采用大肠杆菌菌体蛋白免疫家兔,制备得到高效价抗菌体蛋白抗血清。将经饱和硫酸铵盐析、阴离子交换柱层析和亲和层析纯化的兔抗大肠杆菌菌体蛋白特异性多克隆抗体作为包被抗体和检测抗体,用生物素标记检测抗体,并加入辣根过氧化物酶（HRP）标记的亲和素。结果　建立的大肠杆菌菌体蛋白夹心ELISA检测方法的敏感性为0.32 μg/L,检测范围为1~100 μg/L,与国际同类商品化试剂盒相当。此法具有良好的稳定性,其批内变异系数小于7.7%,批间变异系数小于6.2%。结论  建立了特异、敏感、稳定的检测大肠杆菌菌体蛋白的夹心ELISA试剂盒,为生物制品中残留大肠杆菌菌体蛋白的质量控制提供了一种重要的检测方法。     

鸡胚细胞疫苗制品宿主细胞蛋白残留量检测方法的建立

目的 建立鸡胚细胞疫苗制品中宿主细胞蛋白残留量的检测方法.方法 制备鸡胚细胞蛋白和抗鸡胚细胞蛋白抗体,摸索ELISA双抗体夹心法的试验条件,建立酶联免疫检测方法,并进行各项指标的验证.结果 纯化的鸡胚细胞蛋白抗体纯度达到90％以上,抗体效价可达1∶128.蛋白质印迹法分析显示,纯化抗体与鸡胚细胞蛋白呈现特异性结合.该方...     

人乳头瘤病毒重组蛋白疫苗酶联免疫检测法的建立及其应用

目的建立人乳头瘤病毒重组蛋白疫苗(HPV16 L2E6E7)酶联免疫的检测方法,用于疫苗发酵过程中的重组蛋白表达的监控。方法用常规方法制备兔抗HPV16 L2E6E7多克隆抗体作为包被抗体,商品化小鼠抗HPV16 E7单克隆抗体为检测抗体,夹心ELISA方法检测HPV16 L2E6E7抗原参考品,建立抗原标准曲线,确定线性范围及检测限,同时验证该方法的特异性。结果建立了检测HPV16 L2E6E7抗原含量的夹心ELISA方法,抗原参考品系列浓度在19.53~1 250 ng·m L-1内有很好的线性(R2>0.99)和回收率(90%~110%);特异性好,不受发酵液中宿主菌蛋白的干扰。结论建立了人乳头瘤病毒重组蛋白疫苗重组抗原含量的测定方法,为该疫苗的发酵工艺的质控提供了有效技术手段。     

NMM抗肿瘤DNA疫苗原液大肠杆菌菌体蛋白质残留量检测方法的建立与验证

目的 建立并验证检测NMM抗肿瘤DNA疫苗原液中大肠杆菌菌体蛋白质残留量的双抗体夹心ELISA试验方法。方法 使用双抗体夹心ELISA试验方法检测NMM抗肿瘤DNA疫苗原液中大肠杆菌菌体蛋白残留量,采用四参数logstic曲线进行回归分析,并对该方法的专属性、检测限、定量限、线性与范围、精密度、准确度、耐用性等进行验证,验证通过对5批样品进行检测。结果 采用双抗体夹心ELISA试验方法进行大肠杆菌蛋白质残留量检测时,DNA疫苗原液无需进行稀释。NMM抗肿瘤DNA疫苗原液对大肠杆菌菌体蛋白质的检测无干扰及抑制作用,方法的专属性良好;本法检测限为0.41 ng/ml;定量限为0.98 ng/ml;该方法测定宿主菌蛋白质残留量在0～100 ng/ml范围内线性良好,R2≥0.9999;本方法重复性试验中宿主菌蛋白质含量RSD值均低于15%,中间精密度实验中样品吸光值RSD值低于10%,精密度结果良好。在检测线性范围内加入高、中、低3种浓度的大肠杆菌菌体蛋白,回收率均值为100.35%(n=9,RSD=3.58%);本方法检测实验条件发生微小变动时（不同人员、不同批次试剂盒）,对测定结果的影响...     

检测黑猩猩腺病毒68型抗原的双抗体夹心ELISA的建立

目的  建立定量黑猩猩腺病毒68型（chimpanzee adenovirus type 68，AdC68）含量的双抗体夹心ELISA，并验证其可行性。方法  用表达绿色荧光蛋白（green fluorescence protein，GFP）的非复制型AdC68（AdC68GFP）感染HEK293细胞，收获病变细胞并进行超速离心纯化AdC68GFP。用纯化AdC68GFP免疫家兔制备抗AdC68GFP抗体。以抗AdC68GFP抗体为包被抗体，辣根过氧化物酶标记的抗腺病毒HEXON IgG为酶标抗体，建立双抗体夹心ELISA，确定该法的线性范围，并验证该法的准确度、精密度、专属性和适用性。结果  纯化AdC68GFP的蛋白浓度为38.8 µg/ml，其中HEK293细胞的蛋白浓度低于0.3 µg/ml。双抗体夹心ELISA的最适包被抗体和酶标抗体浓度分别为1∶50和1∶500。该法的线性范围为0.06~3.88 µg/ml，线性相关系数为0.999 6。高、低浓度AdC68GFP样品的回收率分别为93.17%和94.33%，变异系数分别为6.72%和3.44%。该法可特异性检测AdC68GFP抗原，未发现与HEK293细胞蛋白发生交叉反应。应用该法检测AdC68GFP纯化过程中的样品可反映病毒的纯化效果。结论  建立的双抗体夹心ELISA具有良好的准确度、精密度和特异性，可用于AdC68纯化工艺过程中对病毒蛋白含量的快速检测。     

重组人粒细胞集落刺激因子宿主蛋白质含量的测定

目的根据重组人粒细胞集落刺激因子 (rhG CSF)的生产工艺 ,建立宿主蛋白质 (HCP)含量的测定方法。方法用不含rhG CSF基因的空质粒转染E .coli宿主 (BL2 1) ,按rhG CSF的生产工艺进行发酵、纯化、制备HCP。常规法免疫家兔 ,制备抗HCP多抗血清 ,经纯化后 ,过碘酸钠法标记辣根过氧化物酶 (HRP) ,建立双抗夹心酶标记免疫吸附测定 (ELISA)法测定HCP在rhG CSF原液中的含量。结果所建HCP测定方法能够测定 7.8～ 2 5 0ng/ml范围内的HCP。结论重组蛋白质药物宿主蛋白质含量测定应依据不同的工艺 ,制定不同的方法。     

检测脑膜炎球菌多糖疫苗Y群多糖含量和分子大小的双抗体夹心ELISA法的建立和初步应用

目的建立测定A、C、Y、W135群脑膜炎球菌多糖疫苗（groupsA，C，Y，W135meningococ—calpolysaccharidevaccine，MPV4）Y群多糖含量的双抗体夹心ELISA法。方法采用杂交瘤技术制备抗Y群多糖单克隆抗体，并通过过碘酸钠法用辣根过氧化物酶标记单克隆抗体。分别以抗Y群多糖不同位点的单克隆抗体作为包被抗体和酶标二抗，通过优化反应条件来建立双抗体夹心ELISA法，同时进行方法学验证。结果建立的双抗体夹心ELISA法特异性良好，未检出与A、C、W135群多糖的交叉反应。Y群多糖在2．5～20．0ng／ml范围的剂量反应曲线呈现最佳线性关系，相关系数〉0．99。该法的试验内和试验间准确度较好，精密度较佳，定量限度为4ng／ml。采用该法测定3批MPV4Y群多糖显示，Y群多糖的含量、多糖分子大小‰值和回收率的结果均与先前的检定结果一致，符合暂行质量标准。结论建立的双抗体夹心ELISA法可用于MPV4Y群多糖的关键质量指标测定。     

双抗体夹心ELISA法定量检测左旋多巴

目的建立左旋多巴的酶联免疫定量分析方法。方法以左旋多巴与载体蛋白钥孔戚血蓝素偶联,制备免疫抗原Levodopa-KLH。采用杂交瘤技术制备的特异性抗左旋多巴单克隆抗体作为包被抗体,待测左旋多巴为夹心抗原,免疫抗原Levodopa-KLH免疫新西兰兔得到的多克隆抗体为检测抗体,建立了一种定量测定左旋多巴的双抗体夹心ELISA方法。结果左旋多巴浓度在40～2 000 ng/mL范围内呈良好线性关系,Y=0.8367 X+0.3423,相关系数r2=0.993 3,检测限为20 ng/mL。经方法学考核,批内、批间变异系数分别为9.53%和12.77%,平均回收率为87.86%,与卡比多巴、多巴胺、异丙肾上腺素、去甲肾上腺素、肾上腺素、维生素C、5-羟色胺、金刚烷胺基本无交叉反应,健全性分析表明,人血清稀释倍数对该方法无影响,8 d连续检测标准曲线表明稳定性良好。结论这种定量检测左旋多巴的双抗体夹心ELISA方法,灵敏度高,重复性好,为左旋多巴研究提供了定量检测的方法,并为药代动力学、临床血药浓度监测提供备选方法。     

重组溶葡萄球菌酶成品中主药蛋白质含量的测定

目的建立一种反相高效液相色谱法测定重组溶葡萄球菌酶成品中主药蛋白质的含量。方法VydacC18柱(250 mm×4.6 mm,300,5μm),流动相A为0.1%三氟乙酸溶液,流动相B为三氟乙酸-乙腈(1∶999)进行梯度洗脱,流速为1 mL/min,进样量为20μL,检测波长为280 nm。结果重组溶葡萄球菌酶在5~30μg范围内和峰面积之间具有很好的线性关系,相关系数为0.999 8,多次测定的RSD<10%,平均回收率为103.7%,RSD为1.46%。结论此方法可以用于重组溶葡萄球菌酶的含量测定。     

重组溶葡球菌酶的体外抗菌活性研究

目的：评价重组溶葡球菌酶对545株临床分离葡萄球菌的体外抗菌活性。方法：采用平皿二倍稀释法，测定重组溶葡球菌酶对545株葡萄球菌的最低抑菌浓度（MIC）；采用试管二倍稀释法和平皿计数法测定此酶对45株葡萄球菌的最低杀菌浓度（MBC）；采用不同浓度重组溶葡球菌酶不同时间的杀菌结果绘制杀菌曲线，检测其对4株受试葡萄球菌的动态杀菌趋势；此外，测定不同培养条件对MIC的影响。结果：此酶对257株金葡球菌具有较强的体外抗菌活性，对288株凝固酶阴性葡萄球菌的抗菌活性相对较弱；结合MBC和杀菌曲线结果，可以判断此酶对敏感菌为快速杀菌作用，并呈浓度依赖性；pH，细菌接种量及高浓度血清蛋白对MIC有一定影响，受试浓度的二价金属离子对MIC影响不明显。结论：重组溶葡球菌酶主要对金葡菌体现强大的抗菌活性，对耐甲氧西林金葡菌（MRSA）和甲氧西林敏感金葡菌（MSSA）的抗菌作用没有明显差别，有进一步研究的价值。     

Technological evaluation and equivalence assessment of lorazepam tablets in rabbits

Four different oral lorazepam tablets (Tavor tablets as reference preparation and three generic tablet formulations, A, B and C) were investigated after administration to 12 rabbits to evaluate their bioequivalence. A single 2 mg/kg dose was administered orally as powder and lorazepam plasma concentrations were determined by a validated HPLC method. Maximum plasma concentrations (Cmax), of 207 ng/ml (reference), 198 ng/ml (A), 166 ng/ml (B) and 169 ng/ml (C) were achieved. Lorazepam appeared in the plasma at 0.66 h (Tmax) for all formulations, probably because the disintegration step was bypassed due to the pulverization of the administered doses. Areas under the plasma concentration-time curves (AUC(0-t) and AUC(0-infinity)) were determined. The obtained AUC(0-t) values were 556.57 ng h/ml (reference), 554.70 ng h/ml (A), 493.08 ng h/ml (B), and 487.88 ng h/ml (C). ANOVA results (P > or = 0.05) and 90% confidence intervals for the mean ratio (T/R) of AUC(0-t), AUC(0-infinity), and Cmax were within the EMEA acceptance range. Pharmacokinetic and statistical results of this study show that the four tested drug products (Tavor, A, B, C) are to be considered bioequivalent and interchangeable in medical practice.     

量子点荧光探针用于汉坦病毒重组抗原的检测

目的应用量子点荧光探针对汉坦病毒（Hantavirus,HV）重组抗原进行检测。方法合成水溶性量子点荧光纳米颗粒,并在其表面修饰G蛋白和anti-HV抗体作为量子点荧光探针,对HV重组抗原进行检测并优化检测条件。结果量子点与抗体的最佳偶联条件：pH 6.0、反应时间2 h、抗体浓度为20μg/ml。用本方法检测HV重组抗原的最低检测值为5 ng/ml。结论该探针能有效的识别HV抗原,且操作简便快速,为HV重组抗原的检测和肾出血热综合征的诊断提供了新方法。     

红景天苷在比格犬体内绝对生物利用度研究

目的建立比格犬血浆中的红景天苷的HPLC-MS/MS测定方法,研究红景天苷在比格犬体内的绝对生物利用度。方法以天麻素为内标,血浆样品经蛋白沉淀后,经Symmetry RP18(100 mm×4.6 mm,3.5μm)柱分离,使用体积分数0.1%甲酸溶液(A)-含0.1%甲酸和20%乙腈的甲醇溶液(B)作为流动相,进行等度洗脱(35%B),流速为0.4 ml/min,柱温40℃,进样量2μl;通过电喷雾电离源(ESI),以多反应监测(MRM)模式进行负离子检测,红景天苷、天麻素的MRM离子对分别为m/z 299.1→118.9、m/z 285.1→122.9。比格犬分别以口服和静注两种给药方式给予红景天苷原料药,在不同时间点取血,样品采用HPLC-MS/MS法测定,研究红景天苷的药动学及绝对生物利用度。结果红景天苷的质量浓度在10~10000 ng/ml内线性关系良好(r>0.9986),最低定量浓度为10.0 ng/ml。方法回收率为89.5%~91.8%,日内精密度(RSD)<9.7%,日间精密度(RSD)<7.3%。单剂量口服15 mg/kg或静注1.5 mg/kg红景天苷原料药后,cmax分别为(9680±3725)和(9310±1645)ng/ml;tmax分别为(1.25±0.67)和(0.011±0.017)h,AUC0?t分别为(20535.4±5200.0)和(4646.7±720.5)ng·h/ml,AUC0-∞分别为(20607.9±5266.2)和(4691.6±715.2)ng·h/ml;t1/2分别为(1.31±0.63)和(0.98±0.13)h。结论该方法简便快速、灵敏可靠,可用于红景天苷体内过程研究。红景天苷在比格犬体内的绝对生物利用度为(43.9±11.2)%。     

Electrospray LC-MS/MS quantitation,stability, and preliminary pharmacokinetics of bradykinin antagonist polypeptide B201 (NSC 710295) in the mouse

B201 (NSC 710295), [SUIM-(Darg-Arg-Pro-Hyp-Gly-Igl-Ser-Digl-Oic-Arg)(2)], a third generation of bradykinin (BK) antagonist, has been found to possess high potency. We report the development of a highly sensitive electrospray LC-MS/MS assay method for the analysis of B201 in plasma for the first time, using an ion-trap mass spectrometer. Human or mouse plasma (0.2 ml) was spiked with B201 and the internal standard, substance P. The compounds were extracted with a preconditioned C-18 reversed-phase column and analyzed by LC-MS/MS. The analytes were separated on a 50 x 2 mm (i.d.) BetaBasic C8 column, using a gradient elution. The positive ion selected reaction monitor mode was used monitoring the transitions of ions at m/z 938.9(3+)-->816.0(2+) for B201 and 674.3(2+)-->665.7(2+) for substance P. Assay validation was performed, and the limit of quantitation (LOQ) for B201 was found to be 1 ng/ml for human plasma and 2.5 ng/ml for mouse plasma. The recovery was 78% for B201 and 88% for substance P. The assay was linear from 2.5 to 1500 ng/ml for mouse plasma monitored. Using a 0.2 ml plasma, the within-day CVs were 9.3% at 2.5 ng/ml, 6.5% at 100 ng/ml, and 3.8% at 1000 ng/ml for human plasma (n=6). For mouse plasma, the respective within-day CVs were 17.6, 9.6, and 6.2% (n=6). The between-day CVs for human plasma were 8.2, 10.9, and 2.4%, respectively, (n=3) and the respective values for mouse plasma were 11.9, 8.6 and 6.5% (n=6). Pharmacokinetics of B201 in the mouse was studied following i.v. administration at 5 mg/kg and found to conform to a two-compartment model with an initial half-life of 14 min and a terminal half-life of 44 h. Plasma B201 peak level was detected at microg/ml range and the levels were detectable for a least 24 h. Preliminary oral bioavailability was found to be about 1%. This method demonstrates that an ion trap mass spectrometer can be a powerful tool to quantify large peptides at low nanogram per milliliter with a non-isotopically labeled internal standard.     

重组溶葡萄球菌酶对金黄色葡萄球菌生物被膜的体外清除作用

目的研究重组溶葡萄球菌酶对金黄色葡萄球菌生物被膜的体外清除作用。方法使用硅橡胶膜片建立金黄色葡萄球菌生物被膜的体外模型;使用超声震荡—活菌计数法作为金黄色葡萄球菌生物被膜的定量检测方法,分别测定在给予重组溶葡球菌酶及其对照药作用前后金黄色葡萄球菌生物被膜中的活菌数;使用扫描电镜作为金黄色葡萄球菌生物被膜的直观定性检测方法,分别观察在给予重组溶葡球菌酶及其对照药作用前后金黄色葡萄球菌生物被膜的镜下形态。结果经72 h连续培养,金黄色葡萄球菌在硅橡胶片上形成较为成熟的生物被膜,不同浓度重组溶葡球菌酶作用24 h后被膜中的活菌计数明显低于对照药去甲万古霉素,电镜结果进一步支持此结果。结论重组溶葡萄球菌酶能够有效地清除金黄色葡萄球菌生物被膜。     

A UFLC/MS/MS method for simultaneous quantitation of alisol A and alisol B 23-acetate from Alisma orientale (Sam.) Juz. in rat plasma

A sensitive and reliable ultra fast liquid chromatography tandem mass spectrometry (UFLC-MS/MS) method has been developed and validated for simultaneous quantitation of alisol A and alisol B 23-acetate from Alisma orientale (Sam.) Juz. in rat plasma using diazepam as an internal standard (IS). The plasma samples were extracted by liquid–liquid extraction with methyl tert-butyl ether and separated on a Venusil MP C18 column (100 mm × 2.1 mm, 3.0 mm) (Venusil, China) using gradient elution with the mobile phase consisting of methanol and 0.1% acetic acid in water at a flow rate of 0.4 ml/min. The two analytes were monitored with positive electrospray ionization by multiple reaction monitoring mode (MRM). The lower limit of quantitation was 5.00 ng/ml for alisol A and 5.00 ng/ml for alisol B 23-acetate. The calibration curves were linear in the range of 5.00–2500 ng/ml for alisol A and 5–2500 ng/ml for alisol B 23-acetate. The mean extraction recoveries were above 63.8% for alisol A and 68.0% for alisol B 23-acetate from biological matrixes. Both intra-day and inter-day precision and accuracy of analytes were well within acceptance criteria (15%). The validated method was successfully applied to the pharmacokinetic study of alisol A and alisol B 23-acetate in rat plasma after oral administration of alcohol extract of Alismatis Rhizoma.     

高效液相色谱法测定血浆中格列吡嗪的浓度

目的：为研究格列吡嗪的药物动力学及其制剂的开发提供方法。方法：采用ＨＰＬＣ法测定血药浓度。结果：该方法在２０￣１０００ｎｇ／ｍｌ浓度范围内有良好的线性关系,方法回收率达１００％,日内,日间变异系数均小于７％,最低检测浓度达１０ｎｇ／ｍｌ,结论：该方法适合于药物动力学研究。     

Stimulation of enzyme secretion from isolated pancreatic acini by Clostridium difficile toxin B

Exposure of isolated rat pancreatic acini to increasing concentrations (10 ng - 800 ng/ml) of toxin B from Clostridium difficile produced a biphasic effect on the rate of secretion of amylase, trypsinogen, and chymotrypsinogen. Whereas doses of toxin B from 10-30 ng/ml increased enzyme secretion by 15-20%, doses between 30 ng and 60 ng/ml showed a regression of this effect, whereafter the rate of secretion of amylase, trypsinogen, and chymotrypsinogen increased with increasing concentrations of the toxin. Toxin B concentration of 800 ng/ml enhanced amylase, trypsinogen and chymotrypsinogen secretion by 119%, 185% and 195%, respectively, when compared with the basal level. Stimulation of enzyme secretion by toxin B was not affected by the presence of either actinomycin-D or cycloheximide, at a concentration which inhibited acinar RNA or protein synthesis by 80-90%. Although toxin B as well as CCK8, carbachol and secretin by themselves caused significant stimulation in amylase, trypsinogen and chymotrypsinogen secretion from isolated pancreatic acini, toxin B together with either CCK8, carbachol or secretin produced no further augmentation in enzyme secretion than what was observed with the secretagogues alone. It is concluded that toxin B of Cl. difficile exerts a direct effect on pancreatic acinar cells as evidenced by stimulation of enzyme secretion.